ω-3 fatty acid supplements for secondary prevention of cardiovascular disease: From "no proof of effectiveness" to "proof of no effectiveness"

JAMA Internal Medicine

Volumn 173, Issue 15, 2013, Pages 1466-1468

  Messori, Andrea ^a   Fadda, Valeria ^a   Maratea, Dario ^a   Trippoli, Sabrina ^a  

^a Ente Dei Servizi Tecnici di Area Vasta (ESTAV) Toscana Centro   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID;

CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; HUMAN; LETTER; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SECONDARY ANALYSIS; SECONDARY PREVENTION; SEQUENTIAL ANALYSIS; TRIAL SEQUENTIAL ANALYSIS;

EID: 84882287058     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.6638     Document Type: Letter

References (8)

1. Kwak SM, Myung SK, Lee YJ, Seo HG; Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172(9):686-694.
2. Hu FB, Manson JE. Omega-3 fatty acids and secondary prevention of cardiovascular disease-is it just a fish tale? Arch Intern Med. 2012;172(9): 694-696.
3. Halim SA, Newby LK. Review: omega-3 fatty acid supplements provide no protective benefit in cardiovascular disease. Ann Intern Med. 2012;157(4):JC2-JC3.
4. Gruppo Italiano per lo Studio della Sopravvivenza nell'InfartoMiocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E aftermyocardial infarction: results of the GISSI Prevenzione trial [published corrections appear in Lancet. 2001;357(9256):642 and 2007;369(9556):106]. Lancet. 1999;354(9177):447-455.
5. Yokoyama M, Origasa H, Matsuzaki M, et al; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-1098.
6. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysismay establish when firm evidence is reached in cumulativemeta-analysis. J Clin Epidemiol. 2008;61(1):64-75.
7. Brok J, Thorlund K, Gluud C,Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008;61(8):763-769.
8. Albalawi Z,McAlister FA, Thorlund K,Wong M,Wetterslev J. Random error in cardiovascular meta-analyses: how common are false positive and false negative results? [published online December 3, 2012]. Int J Cardiol. doi:10.1016/j.ijcard.2012.11.048.